What is the 13F Pro Quality Score for LMAT?

13F Pro ranks LEMAITRE VASCULAR INC (LMAT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LMAT's current score at https://13fpro.ai/research/LMAT (free sign-up required for the full ranking).

Which hedge funds own the most LMAT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LMAT include BlackRock,, Conestoga Capital Advisors,, FIRST ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LMAT as soon as new 13F filings post.

Where does 13F Pro source LMAT data?

All LEMAITRE VASCULAR INC fundamentals and ownership data come directly from SEC EDGAR. LEMAITRE VASCULAR INC files with the SEC under CIK 1158895. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LMAT in?

LEMAITRE VASCULAR INC (LMAT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LMAT research updated on 13F Pro?

LMAT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LEMAITRE VASCULAR INC(LMAT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1158895 LMAT stock profile & AI dashboard →

13F Pro Quality Score

69.1/100

Rank #384 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

71.0/100

Profitability

88.4/100

Balance Sheet

85.5/100

Earnings Quality

79.5/100

Free Cash Flow

83.2/100

Institutional Flow

45.5/100

Revenue Scale

27.1/100

Dilution Risk

32.7/100

LMAT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LEMAITRE VASCULAR INC (LMAT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LMAT at 69.1/100 on a 32-signal composite quality model, placing it at rank #384 of 2,879 stocks — the top 25% of the AI-ranked universe. LMAT scores in the top quartile across profitability (88.4), balance sheet strength (85.5), free cash flow (83.2). Areas of concern include revenue scale (27.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 32.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), LEMAITRE VASCULAR INC reports quarterly revenue of $66.6M, net income of $15.7M, an operating margin of 26.7%. Top institutional holders of LMAT by reported 13-F value include BlackRock,, Conestoga Capital Advisors,, FIRST ADVISORS, based on the most recent SEC filings. LMAT trades on the Nasdaq exchange and files with the SEC under CIK 1158895. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LMAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LEMAITRE VASCULAR INC directly from SEC EDGAR. LEMAITRE VASCULAR INC's 13F Pro composite quality score has ranged between 8 and 78 since 2021, currently 69.1 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$66.6M

Net Income

Q1 2026

$15.7M

Free Cash Flow

Q1 2026

$12.3M

Operating Margin

Q1 2026

26.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+13.5% YoY

$249.6MFY 2025

FY21 $154.4MFY22 $161.7MFY24 $219.9MFY25 $249.6M

Net Income

+31.2% YoY

$57.7MFY 2025

FY21 $26.9MFY22 $20.6MFY24 $44.0MFY25 $57.7M

Operating Income

+30.0% YoY

$67.9MFY 2025

FY21 $36.4MFY22 $26.8MFY24 $52.3MFY25 $67.9M

EPS (Diluted)

+30.6% YoY

$2.52FY 2025

FY21 $1.25FY22 $0.93FY24 $1.93FY25 $2.52

Total Assets

+11.6% YoY

$615.7MFY 2025

FY21 $292.8MFY22 $310.5MFY24 $551.8MFY25 $615.7M

Op. Cash Flow

+84.1% YoY

$81.3MFY 2025

FY21 $35.1MFY22 $25.4MFY24 $44.1MFY25 $81.3M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$249.6M +13.5%	$219.9M +36.0%	$161.7M +4.7%	$154.4M +19.4%	$129.4M +22.5%	$105.6M
Net Income	$57.7M +31.2%	$44.0M +113.2%	$20.6M -23.3%	$26.9M +26.8%	$21.2M -7.5%	$22.9M
Operating Income	$67.9M +30.0%	$52.3M +94.8%	$26.8M -26.3%	$36.4M +26.5%	$28.8M +2.1%	$28.2M
EPS (Diluted)	$2.52 +30.6%	$1.93 +107.5%	$0.93 -25.6%	$1.25 +20.2%	$1.04 -8.0%	$1.13
Total Assets	$615.7M +11.6%	$551.8M +77.7%	$310.5M +6.0%	$292.8M +15.8%	$252.8M +65.1%	$153.1M
Operating Cash Flow	$81.3M +84.1%	$44.1M +73.9%	$25.4M -27.7%	$35.1M +0.9%	$34.8M +78.4%	$19.5M

AI Insight: LMAT Ratio Trends

LeMaitre's profitability surged to a multi-quarter peak in Q3 2025 — ROIC hit 21.4% — before a modest seasonal pullback in Q4 2025 and Q1 2026.

• Operating margin rebounded sharply from a trough of 21.1% in Q1 2025 to 33.3% in Q3 2025, a 12.2pp swing in two quarters.

• ROIC followed the same arc: bottoming at 14.5% in Q1 2025, peaking at 21.4% in Q3 2025, then easing to 17.5% in Q1 2026.

• Q1 2026 OpMargin of 26.7% and ROIC of 17.5% remain comfortably above the Q1 2025 trough, suggesting structural improvement.

⚠ ROA dropped to 7.9% in Q1 2025 — the lowest in the dataset — hinting at periodic asset-efficiency pressure worth monitoring each Q1.

⚠ Q3 2025 metrics look exceptional; confirm whether the 33.3% OpMargin reflects a one-off item or genuine operating leverage.

Get alerted when LMAT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LEMAITRE VASCULAR INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LMAT

BlackRock, Inc.
$343.2M3,144,151 sh
Conestoga Capital Advisors, LLC
$161.2M1,476,813 sh
FIRST TRUST ADVISORS LP
$109.0M998,071 sh
VANGUARD CAPITAL MANAGEMENT LLC
$99.6M912,058 sh
Copeland Capital Management, LLC
$95.1M870,692 sh
STATE STREET CORP
$93.4M855,784 sh
CONGRESS ASSET MANAGEMENT CO /MA
$91.1M834,529 sh
GENEVA CAPITAL MANAGEMENT LLC
$82.3M753,992 sh
GEODE CAPITAL MANAGEMENT, LLC
$71.9M658,445 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$61.4M562,770 sh

Fund	Value	Shares
BlackRock, Inc.	$343.2M	3,144,151
Conestoga Capital Advisors, LLC	$161.2M	1,476,813
FIRST TRUST ADVISORS LP	$109.0M	998,071
VANGUARD CAPITAL MANAGEMENT LLC	$99.6M	912,058
Copeland Capital Management, LLC	$95.1M	870,692
STATE STREET CORP	$93.4M	855,784
CONGRESS ASSET MANAGEMENT CO /MA	$91.1M	834,529
GENEVA CAPITAL MANAGEMENT LLC	$82.3M	753,992
GEODE CAPITAL MANAGEMENT, LLC	$71.9M	658,445
VANGUARD PORTFOLIO MANAGEMENT LLC	$61.4M	562,770

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LMAT on your watchlist

Track score changes the day LEMAITRE VASCULAR INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LMAT a good stock to buy?

13F Pro's AI-powered analysis of LEMAITRE VASCULAR INC (LMAT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LMAT are available on the LMAT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LMAT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LMAT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LEMAITRE VASCULAR INC's investment landscape.